Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Debt / NOTE 0.599% 8/0
-
Number of holders
-
39
-
Total 13F principal, excl. options
-
400,691,200
-
Principal change
-
+400,691,200
-
Total reported value, excl. options
-
$406,783,596
-
Value change
-
+$406,783,596
-
Number of buys
-
39
-
Price
-
$1.02
Significant Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q3 2017
39 filings reported holding 09061GAH4 - BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q3 2017.
BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 has 39 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $400,691,200 of principal
.
Largest 10 bondholders include Linden Advisors LP ($38,500,000 of principal), SILVERBACK ASSET MANAGEMENT LLC ($36,000,000 of principal), Allianz Asset Management GmbH ($27,200,000 of principal), ROYAL BANK OF CANADA ($26,150,000 of principal), ADVENT CAPITAL MANAGEMENT /DE/ ($26,000,000 of principal), Polar Asset Management Partners Inc. ($25,000,000 of principal), JPMORGAN CHASE & CO ($18,255,000 of principal), STATE STREET CORP ($16,750,000 of principal), BAKER BROS. ADVISORS LP ($15,000,000 of principal), and LAZARD ASSET MANAGEMENT LLC ($13,500,000 of principal).
This table shows the top 39 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.